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ABSTRACT 
Activation of the retinoic acid (RA) signaling pathway is important for controlling 
embryonic stem cell differentiation and development. Modulation of this pathway occurs 
through the recruitment of different epigenetic regulators at the retinoic acid receptors 
(RARs) located at retinoic acid responsive elements (RAREs) and/or RA-responsive 
regions of RA-regulated genes. Coactivator-associated arginine methyltransferase 1 
(CARM1, PRMT4) is a protein arginine methyltransferase that also functions as a 
transcriptional coactivator. Previous studies highlight CARM1’s importance in the 
differentiation of different cell types. We address CARM1 function during RA-induced 
differentiation of murine embryonic stem cells (mESCs) using shRNA lentiviral 
transduction and CRISPR/Cas9 technology to deplete CARM1 in mESCs. We identify 
CARM1 as a novel transcriptional coactivator required for the RA-associated decrease 
in Rex1 (Zfp42), and for the RA induction of a subset of RA-regulated genes, including 
CRABP2 and NR2F1 (Coup-TF1). Furthermore, CARM1 is required for mESCs to 
differentiate into extraembryonic endoderm in response to RA. We next characterize the 
epigenetic mechanisms that contribute to RA-induced transcriptional activation of 
CRABP2 and NR2F1 in mESCs and show for the first time that CARM1 is required for 
this activation. Collectively, our data demonstrate that CARM1 is required for 
transcriptional activation of a subset of RA target genes, and we uncover changes in the 
recruitment of Suz12 and the epigenetic H3K27me3 and H3K27ac marks at gene 
regulatory regions for CRABP2 and NR2F1 during RA-induced differentiation.  
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INTRODUCTION 
The processes by which stem cells are able to maintain their self-renewal 
potential versus undergo differentiation are of intense interest given the potential 
therapeutic applicability of stem cell manipulation. Embryonic stem cells (ESCs) 
undergo differentiation in the presence of the vitamin A metabolite, retinoic acid (RA), 
via activation of nuclear retinoic acid receptors (RAR α, β, & γ), members of the nuclear 
receptor (NR) family of proteins1, 2. The retinoid X receptor (RXR)/RAR heterodimer is 
bound to DNA at retinoic acid responsive elements (RAREs) of specific RA-regulated 
genes1. The ability of stem cells to differentiate along several cell lineages is in part a 
result of the regulation by RA signaling of post-translational modifications (PTMs) of 
proteins, including chromatin, by various epigenetic regulators2. Specifically, binding of 
the agonist RA to the RARs results in rapid loss of the epigenetic regulatory polycomb 
repressive complex 2 (PRC2) from various RAREs and promoter regions of RA 
responsive genes; this is accompanied by the transcriptional activation of these genes 
involved in cell differentiation1-3. These RA-associated changes in covalent 
modifications occur on both histone and non-histone proteins1, 3. 
Lysine methylation is one modification that is associated with transcriptional 
activation or repression of genes during ESC differentiation by RA, depending on the 
specific lysine modified1. This network of epigenetic regulation has been widely studied 
in the model system of RA-induced ESC differentiation1. Another important, but less 
well understood modification in the context of RA-induced ESC differentiation is arginine 
methylation by protein arginine methyltransferases (PRMTs)4, 5, the focus of this work. 
Protein arginine methylation plays a role in various cellular processes, such as 
transcriptional control and cell signaling6-11. PRMTs methylate their substrates via the 
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enzymatic transfer of a methyl group from the S-adenosyl-L-methionine cofactor (SAM) 
to the guanidino nitrogens of arginine residues12, 13. PRMT1, PRMT6, and PRMT8 play 
roles in RA-induced neuronal differentiation of ESCs4, 5. PRMT1 and PRMT6 both limit 
the transcriptional activation of some RA-inducible target genes4, 5, while PRMT8 is 
required for the activation of specific neuronal genes4. Coactivator-associated arginine 
methyltransferase 1 (CARM1, also referred to as PRMT4) functions as a coactivator of 
several NR family proteins, including estrogen receptor alpha (ERα) and the androgen 
receptor (AR)11, 14-16. CARM1 mediates transcriptional activation of NR downstream 
targets via association with other coactivators, such as p300/CBP10, 17. Direct 
methylation of p300/CBP by CARM1 alters p300/CBP function10. However, though there 
is evidence that CARM1 indirectly interacts with RARs in an RXR/RAR chromatin-based 
in vitro transcription system to mediate transcriptional activation10, the effects of CARM1 
on RA target genes have not been characterized in ESCs. Here we delineate the role of 
CARM1 in ESC RA-induced differentiation.  
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RESULTS 
Generation and characterization of stable mCARM1 shRNA knockdown (KD) and 
CRISPR/Cas9 knockout (KO) murine embryonic stem cell (mESC) lines. 
We first demonstrated that CARM1 is expressed during mESC RA-induced 
differentiation (Fig. 1A-B). We next analyzed the functions of CARM1 during this 
differentiation. To assess the role of CARM1 in ESCs we used shRNA lentiviral 
transduction18 to generate a stable knockdown (KD) of CARM1 in J1 parental (WT) 
mESCs (cell line #9117). We confirmed decreased CARM1 transcript and protein levels 
in the CARM1 KD line in comparison to the J1 WT and shRNA control (shCtl) mESCs 
(Fig 1C). CARM1 protein levels were 97.3% ± 1.5% SE lower than in WT cells, while 
CARM1 levels in shCtl and WT cells were similar (98.1% ± 14.2% SE). To confirm 
decreased CARM1 function, we measured protein levels of me-PABP1 (methylated-
Poly(A)-binding protein 1), an established non-histone protein target of CARM119. 
Levels of me-PABP1 were also 81.1% ± 5.0% SE lower in the CARM1 KD compared to 
WT (Fig. 1D), indicating that CARM1 activity is also much lower in the CARM1 KD cells. 
Low, residual levels of CARM1 in an MCF7 CARM1 KD cell line had an impact on the 
level of its me-PABP1 substrate 20. Thus, to abolish CARM1 activity completely in 
mESCs we next generated a CARM1-/- (KO) J1 mESC line using CRISPR-Cas9 
technology (cell line #23). CARM1 protein was undetectable in the CARM1 KO cell line 
in comparison to the WT and the shRNA CARM1 KD cell line (Fig. 1C). Similarly, we did 
not detect any me-PABP1 protein in the CARM1 KO (Fig. 1D), indicating that CARM1 
activity is lost in the CARM1 KO cell line. 
CARM1 methylates numerous cellular proteins, and loss of CARM1 function 
could potentially impair cellular proliferation. We found no changes in cell proliferation in 
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the stable CARM1 KD and CARM1 KO cell lines compared to both WT and the shCtl 
mESCs (Fig. 1E). This result indicates that CARM1 depletion has no effect on the rate 
of mESC proliferation. 
Stable CARM1 knockout does not affect pluripotency but does prevent the RA-
associated decrease in Rex1 (Zfp42). 
Previous research has shown that transient CARM1 depletion in human and 
murine embryonic stem cells (hESC and mESC, respectively) via siRNA methodology 
results in the initiation of cellular differentiation21, 22. To address whether stable lack of 
CARM1 affects pluripotency, we used qRT-PCR to measure the transcript levels of key 
pluripotency genes, including Nanog, Oct4, Rex1, and Sox2, in our stable CARM1 KD 
and CARM1 KO cell lines in comparison to WT. We found no differences in the levels of 
these transcripts in the absence of RA in the three cell lines (Fig. 2A). Additionally, we 
did not detect any differences in Nanog and Oct4 protein levels between the WT and 
CARM1 KO cells (Fig. 2B). Since RA decreases the transcripts of Nanog, Oct4, Rex1, 
and Sox2 in differentiating WT mESCs1, 2, we ascertained if the loss of CARM1 affects 
these transcript levels. Interestingly, we found that loss of CARM1 prevented the 
decrease in Rex1 (Zfp42) transcripts in response to RA, whereas Nanog, Oct4 and 
Sox2 mRNAs were similar in CARM1 KO mESCs compared to RA-treated WT mESCs 
(Fig. 2A). This implicates CARM1 as a regulator of Rex1, a key pluripotency-associated 
gene.  
Decreased CARM1 level reduces transcript levels of a subset of RA-inducible 
genes. 
We next identified transcripts that changed between the WT and the CARM1 KD 
cells upon RA addition. Given the role of CARM1 as a histone methyltransferase that 
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deposits activating epigenetic marks13 and as a coactivator of other NRs11, 14-16, we 
hypothesized that the lack of CARM1 would limit RA-regulated gene transcription. We 
treated J1 WT, shCtl, and CARM1 KD cells with vehicle (0.1% EtOH) or 1 µM RA for 48 
hrs and measured the transcript levels of a number of well characterized RA-inducible 
genes, including CRABP2, Cyp26b1, HoxA1, NR2F1, and NR2F2; these genes play key 
roles during RA-induced differentiation of ESCs1, 2. For example, CRABP2 and Cyp26b1 
are involved in RA metabolism and transport23-25. CRABP2 is responsible for 
transporting RA from the cytoplasm into the nucleus25. Hoxa1 is a transcription factor 
required for ESC differentiation into neuronal cells26 and NR2F1 is involved in RA-
induced parietal endoderm differentiation27. We showed that CARM1 depletion 
diminished RA-induction of some of the transcripts measured (Fig. 3A-B), suggesting 
different classes of RA-inducible genes. We found that CRABP2, Cyp26b1, NR2F1, and 
NR2F2 transcripts were induced to a lesser extent in the RA treated CARM1 KD 
compared to RA treated WT and shCtl cell lines (Fig. 3A-B). We also found that 
CRABP2, Cyp26b1, NR2F1, and NR2F2 transcripts were induced to a lesser degree in 
the CARM1 KO compared to the WT cells (Fig. 3A-B). In contrast, we found that Hoxa1 
and RARβ2 transcripts were induced to similar levels in all four cell lines after RA 
addition, indicating that CARM1 depletion had no detectable effect on the RA-induced 
increase in Hoxa1 and RARβ2 mRNAs (Fig. 3A-B). 
To extend and validate our semi-qPCR results, we treated the J1 WT, shCtl, and 
CARM1 KD cell lines with or without 1 µM RA for 48 hrs and performed genome-wide 
transcriptomics. By analyzing our RNA-seq data we generated a list of 101 genes 
whose RA-induced transcript levels were altered by at least 2-fold in the absence of 
CARM1 (Supplemental Table 1). CRABP2, Cyp26b1, NR2F1, and NR2F2 were present 
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among these 101 genes, further supporting our initial data focused on genes in the RA 
signaling pathway (Fig. 3). 
CARM1 depletion decreases RA-induced extraembryonic endoderm gene 
expression. 
Previously our lab has shown that overexpression of NR2F1 in J1 mESCs 
enhances the RA-induction of the extraembryonic endoderm marker genes Gata4, 
Gata6, Lamβ1, and Sox1727. These genes, and PDGFRα and Sox 7 are definitive 
markers of differentiated, extraembryonic endoderm cells28. Therefore, we measured 
these transcripts at 48 and 72 hrs after RA addition to assess the functional 
consequences of the reduced NR2F1 induction observed in the absence of CARM1 
(Fig. 4, and by qRT-PCR in Supplemental Fig. 1). Since residual levels of CARM1 can 
impact its substrates20 we only used the CARM1 KO in which CARM1 is completely 
absent (Fig. 1C). Gata6 transcripts were induced to a lesser degree in the CARM1 KO 
than in WT cells by RA by 67.1% ± 4.2% SE (p<0.0001) and 67.5% ± 4.9% SE 
(p<0.0001) after 48 and 72 hrs RA addition, respectively (Fig. 4A-B). After 72 hrs of RA 
treatment Gata4, Lamβ1, PDGFRα, and Sox7 transcript levels in the CARM1 KO were 
73.0% ± 12.5% SE (p<0.0001), 55.6% ± 3.6% SE (p<0.0001), 59.4.0% ± 6.0% SE 
(p<0.0001), and 44.5% ± 12.5% SE (p<0.05), respectively, of levels in the J1 WT cells 
(Fig. 4A-B). Moreover, Sox17 transcripts were not detectable in the CARM1 KO 
compared to the J1 WT cells at 72 hrs after RA addition. The minimal induction of 
Gata4, Gata6, Lamβ1, PDGFRα, Sox7, and Sox17 transcripts in CARM1 KO cells 
indicates that CARM1 enhances RA-induced, extraembryonic endoderm differentiation 
of mESCs because CARM1 is needed for the increase in NR2F1 transcripts by RA. 
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CARM1 associates with the RA-inducible target genes with and without RA 
treatment. 
We next investigated the mechanism(s) by which lack of CARM1 affects 
transcriptional activation during RA-induced ESC differentiation. Since CARM1 acts as 
a coactivator of other NRs11, 14, 16, we performed ChIP-qPCR analysis on J1 WT cells 
treated with or without RA for 24-72 hrs. We focused on identifying CARM1 occupancy 
near known RARE sites of CRABP2, specifically RARE124, and the NR2F1 PRefSeq 
promoter RA responsive region previously characterized in our lab18 (Fig. 5A). In 
parallel, we measured the binding of CARM1 near the known RARE site of Hoxa129 
(Fig. 5A), since RA-induced activation of Hoxa1 is not affected by CARM1 depletion 
(Fig. 3A-B). We found that CARM1 is present near the Hoxa1 and CRABP2 RAREs and 
near the NR2F1 PRefSeq promoter in the absence of RA (Fig. 5B). Furthermore, upon 
addition of RA CARM1 binding did not increase near the RARE1 of CRABP2 or the 
PRefSeq region of NR2F1 (Fig. 5B), suggesting that in J1 WT cells CARM1 association 
with CRABP2 and NR2F1 is not dynamically regulated in response to RA. Similarly, we 
detected H3R17me2a near the RARE1 of CRABP2 and the PRefSeq region of NR2F1, 
and this mark did not increase after RA addition (Supplemental Fig. 2). We note that 
CARM1 association with CRABP2 and NR2F1 follows the overall levels of CARM1 
protein (compare with Fig. 1B). 
CARM1 depletion affects the chromatin signatures on a subset of RA-inducible 
target genes. 
Histone tails are subject to multiple covalent modifications, which can function 
synergistically or antagonistically. These modifications placed by different histone 
modifying enzymes can occur on neighboring or nearby amino acid residues and adds 
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another mechanism by which genes are regulated30. For example, acetylation of lysine 
(K) 18 on Histone 3 (H3) by CBP/p300 is required prior to H3R17 dimethylation by 
CARM1 near the ERα target gene pS231. Given the proximity of K18 and R17, CARM1 
depletion may affect the dynamic interaction between these two different epigenetic 
marks, implicating CARM1 methylation activity in the regulation of RA-inducible genes. 
CARM1 also mediates dimethylation of R26 on H313, which is adjacent to K27 on H3. 
The trimethylation of H3K27 is often associated with transcriptional repression32 and the 
trimethyl mark is deposited by the Suz12 containing-PRC2 complex near the NR2F1 
PRefSeq promoter18. For this reason, we measured the effects of the CARM1 knockout on 
the association of Suz12, a core component of the PRC2 complex, and on the 
H3K27me3 levels with the PRefSeq region of NR2F1 and the RARE1 of CRABP2 after RA 
addition.  
Our results show that Suz12 binding decreases near NR2F1 PRefSeq in RA treated 
WT cells, but not in CARM1 KO cells. Levels of Suz12 are 1.43-fold ± 0.06 SE (p<0.01) 
and 1.65-fold ± 0.18 SE (p<0.05) higher in the KO cells compared to WT at 48 and 72 
hrs of RA treatment, respectively (Fig. 6A). In contrast, levels of Suz12 near the 
CRABP2 RARE1 did not change with addition of RA to WT cells, but Suz12 levels near 
the CRABP2 RARE1 were 2.09-fold ± 0.06 SE (p<0.01) and 1.82-fold ± 0.05 SE 
(p<0.01) higher in the KO cells at 48 and 72 hrs of RA treatment, respectively, than in 
WT cells. Suz12 levels were similar in WT and CARM1 KO cells near the Hoxa1 RARE, 
with and without RA (Fig. 6A). These data show that the lack of CARM1 increases 
Suz12 association with RA responsive regions in NR2F1 and CRABP2, but not in 
Hoxa1.  
Since PRC2 deposits the repressive H3K27me3 mark, we measured H3K27me3 
11 
 
occupancy near the same genomic regions. We found that while H3K27me3 levels 
gradually decrease near the NR2F1 PRefSeq region in WT cells following RA treatment, 
H3K27me3 levels increase in the CARM1 KO cells. Specifically, H3K27me3 levels near 
NR2F1 PRefSeq are increased by 2.70-fold ± 0.52 SE (p<0.05) in the CARM1 KO cells 
compared to the WT cells after 72 hrs RA treatment (Fig. 6B). H3K27me3 levels near 
the CRABP2 RARE1 do not change with the addition of RA in the WT cells and these 
levels are similar in the CARM1 KO cells (Fig. 6B). When we compare the H3K27me3 
marks near the Hoxa1 RARE we see similar decreases in H3K27me3 levels in WT and 
CARM1 KO cells after RA addition (Fig. 6B) that correlate with the decreases in Suz12 
observed in both cell lines (Fig. 6A).  
The H3K27 residue can also be acetylated, which is frequently associated with 
transcriptional activation33. Increased acetylation on H3K27 near the Hoxa1 RARE 
contributes to RA-induced transcriptional activation of Hoxa1 by RA34. Therefore, we 
measured H3K27ac levels near the CRABP2 RARE1 and near the NR2F1 PRefSeq 
region +/- RA in the WT and CARM1 KO cell lines. We found that in the WT cells the 
H3K27ac mark increased near the CRABP2 RARE1 at 48 and 72 hrs after RA addition, 
but this mark did not change near the NR2F1 PRefSeq region (Fig. 6C). In the CARM1 KO 
cells the levels of H3K27ac decreased by 2.53-fold ± 0.39 SE (p<0.05) and 3.1- fold ± 
0.52 SE (p<0.05) at 48 and 72 hrs after RA treatment, respectively, near the CRABP2 
RARE1 (Fig. 6C). These results highlight the differential epigenetic signatures that may 
contribute to the RA-induced increases in CRABP2 and NR2F1 transcript levels in the 
WT cells. Overall loss of CARM1 affects Suz12 recruitment and its corresponding 
repressive H3K27me3 mark near the NR2F1 PRefSeq region and the activating H3K27ac 
mark near the CRABP2 RARE1.  
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DISCUSSION 
Identification of a novel subset of RA-target genes that require CARM1. 
Given the important role RA signaling plays in stem cell differentiation and 
development1, 2, we determined the role of CARM1 in RA-induced ESC differentiation 
using our stable CARM1 KD and CARM1 KO mESC lines. We show that CARM1 is 
required for the RA-induction of a subset of RA-inducible genes (CRABP2, Cyp26b1, 
NR2F1, and NR2F2). Our results delineate at least two groups of RA-inducible target 
gene sets, one of which is affected by CARM1 depletion. These results suggest 
different mechanisms of action responsible for maximal gene induction by RA and 
demonstrate the importance of epigenetic regulatory proteins, such as CARM1, for 
these processes in mESCs. 
CARM1 is required for RA-induced differentiation of mESCs into extraembryonic 
endoderm. 
The impaired differentiation of these CARM1 KO mESCs along the 
extraembryonic endoderm lineage highlights the importance of CARM1 in RA-induction 
of NR2F1 transcript levels, as NR2F1 is a transcription factor involved in specific 
differentiation programs27. RA-induction of NR2F1 has been reported to repress 
expression of the differentiation associated homeobox transcription factor Cdx1 in the 
caudal embryo35. This occurs via the ability of NR2F1 to compete with RXR/RAR 
binding specifically at the RARE of Cdx135. In P19 embryonal carcinoma cells, NR2F1 
can also repress Oct436 by competing with RXR/RAR binding at the RAREoct site of 
Oct436. We did not see an effect of the loss of CARM1 on Oct4 expression, and future 
work is needed to determine if the absence of NR2F1 expression subsequent to 
depletion of CARM1 affects RA-induction of Cdx1 transcripts. CARM1 loss may 
13 
 
facilitate or block differentiation into other germ layers, but the reduced RA-induction of 
Gata4, Gata6, Lamβ1, PDGFRα, Sox7, and Sox17 transcripts we detected in the 
CARM1 KO cells indicates that CARM1 is required for the differentiation of mESCs into 
extraembryonic endoderm, potentially through NR2F1’s regulation of these 
extraembryonic endoderm genes.  
CARM1 is not required for pluripotency in ES stable KD and KO cells. 
Previous studies have shown that the short-term loss of CARM1 results in 
spontaneous differentiation of untreated mESCs21, 22 and that CARM1 activity results in 
preferential contribution of cells to the inner cell mass rather than the trophectoderm37, 
38. We have shown that ES cells without CARM1 functionally behave like ES cells and 
express the pluripotency transcripts of Nanog, Oct4, Rex1, and Sox2. We note that one 
difference between our data and those of other groups21, 22 is that we generated stable 
CARM1 depletion mESC lines by shRNA and CRISPR/Cas9 methodologies, whereas 
other reports21, 22 described the use of cells in which CARM1 was knocked down for 
three and eight days by siRNA technology21, 22. We used CRISPR/Cas9 as a 
complementary method to target CARM1 for depletion to avoid possible off-target 
effects from siRNA methodology39. After stable CARM1 loss in the mESCs, we detected 
no differences in the basal expression of pluripotency transcripts. It is known that 
CARM1 is necessary for normal development since CARM1-/- mice are not viable and 
die shortly after birth40, 41. However, these CARM1-/- mice are able to develop 
throughout their full term and die primarily from defects such as the improper 
differentiation of their myosatellite cells, adipocytes, and pulmonary epithelial cells 
during development14, 40, 42, 43. Importantly, in the CARM1 KO cells the transcript levels 
of Rex1 (Zfp42) remained high even in the presence of RA, suggesting that CARM1 is 
14 
 
required for RA to negatively regulate the transcript levels of the stem cell marker, 
Rex144. 
The complex epigenetic dynamics involved in controlling gene activation during 
RA-induced differentiation of CARM1 target genes. 
Although the Hoxa1, CRABP2, and NR2F1 genes studied here are all known to 
be increased at the mRNA level by RA treatment in WT ESCs1, 2, 23, 24, our results show 
differences in their epigenetic regulation following the addition of RA. These findings 
support a distinction between different groups of RA-inducible genes based on how they 
are regulated at the epigenetic level18. Moreover, Gillespie and Gudas45 showed that 
Suz12 was removed from the Hoxa1 and RARβ2 RAREs within 30 min. – 4 hrs after RA 
addition. Laursen et al.18 reported that knockdown of the Suz12 protein in the PRC2 
complex in mESCs further increased the transcript levels of NR2F1 and NR2F2 after 
RA treatment18. Here we found that upon depletion of the CARM1 protein NR2F1/2 
transcripts are induced after RA addition to a lesser extent than in the parental WT and 
shCtl mESC lines. The H3R26me2 modification is favored by acetylation of K2746, and 
we therefore speculate that the opposing effects of CARM1 and Suz12 on the regulation 
of NR2F1 may reflect mutually exclusive histone modifications. 
To determine if CARM1 binding is necessary for the RA-induction of CARM1 
target genes, we performed ChIP-qPCR analyses in WT mESCs. We focused on the 
NR2F1 and CRABP2 loci as representative of genes that require CARM1 for RA-
induction and Hoxa1 as a gene that does not require CARM1 for RA-induction. In the 
WT mESCs we found that CARM1 and H3R17me2a were present in the absence of RA 
near the PRefSeq region of NR2F1 and near RARE1 of CRABP2, but contrary to our 
hypothesis, CARM1 and H3R17me2a levels did not increase at these regions upon RA 
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addition to the WT mESCs. We also detected CARM1 binding near the Hoxa1 RARE in 
WT mESCs. CARM1 is detected near the Hoxa1 RARE, but the RA-induction of Hoxa1 
is not dependent on CARM1 levels in WT cells. Our results show that an increase in 
CARM1 occupancy near the NR2F1 PRefSeq promoter and RARE1 of CRABP2 is not 
necessary for the RA-induction of CRABP2 and NR2F1 in WT cells, but CARM1 is 
required for RA to increase their transcript levels (Fig. 7 for model).  
Application of newly identified CARM1 effects in other cellular contexts. 
Our work in identifying RA-induced genes regulated by CARM1 in WT mESCs 
allows us to expand the growing list of CARM1 targets identified over the past few 
years10, 17, 20, 42, 43, 47, 48. Other substrates of CARM1 include transcription factors (Pax7 
and RUNX1)42, 47, splicing factors (CA150)48, and transcriptional coactivators 
(p300/CBP, NCoa3)10, 17, 49. Identification of these substrates and others has implicated 
overexpression of CARM1 in the progression of breast cancer12, 20 and in the 
differentiation of different cell types14, 40, 42, 43. The different functions of CARM1 targets 
emphasize its versatility as a PRMT and/or coactivator and establish CARM1 as 
important for a variety of different cellular processes, now including mESC RA-induced 
differentiation. From our list of genes requiring CARM1, the two exemplary genes that 
we focused on are NR2F1 and CRABP2 since some data has been published 
concerning their RA regulation18, 24. Additionally, NR2F1 and CRABP2 have been 
implicated in diseases such as cancer50, 51, and NR2F1 is important for neurogenesis 
and is highly expressed in the nervous system during development52. Since the roles of 
other PRMTs have been studied in RA-induced neuronal differentiation of ESCs4, 5, in 
future work it will be illuminating to determine if CARM1 plays a role in RA-induced 
neuronal differentiation of ESCs given its role in regulating NR2F1 in our ESC model of 
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differentiation into parietal endoderm cells.  
In conclusion, our study highlights a novel role for CARM1 in RA-induced ESC 
differentiation and defines how CARM1 is required for the induction of key RA-inducible 
genes. In this study we identified novel genes regulated by CARM1 and uncovered a 
requirement for CARM1 in the RA-induced differentiation of ESCs into extraembryonic 
endoderm.  
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Materials and Methods 
Cell culture. 
J1 murine embryonic stem cell lines were plated and grown in gelatin-coated 
plates as described18. All cell counts were performed using a cell and particle counter 
(Z1 Particle Counter; Beckman-Coulter). 
Generation of CARM1 knockdown (KD) J1 mESCs via shRNA lentiviral 
transduction. 
HEK293T cells were co-transfected with either 20 µg pLKO.1-puro CARM1 
shRNA (Sigma, cat# TRCN0000039117, “sh9117”: 5’-
CCGGCCACGATTTCTGTTCTTTCTACTCGAGTAGAAAGAACAGAAATCGTGGTTTTT
G-3’) or shscramble control vector (Sigma, cat# SHC002), 15 µg packaging plasmid 
pCMVΔR8.9, and 5 µg envelop plasmid pVSV-G using Lipofectamine 2000 (Invitrogen). 
Lentiviral particles were collected after 48 hrs and infected into J1 WT mESCs with 
polybrene (10 µg/mL). After 48 hrs, cells were grown in 5 µg/mL puromycin selection 
media for 1-2 weeks to develop antibiotic resistant colonies. 
Generation of CARM1 KO J1 mESCs via CRISPR/Cas9 Flip ‘n’ Glow. 
CARM1Ex4 (105bp) is inverted by cre-mediated recombination to cause loss of 
Carm1 function by introducing a fusion with EGFP after exon 3. The Carm1-EGFP 
transition codes for SSAVNYFN-FMVSKGEELFT (italics indicate EGFP). Expression of 
the EGFP fusion is controlled by the CARM1 promoter. We ligated the pBig CARM1-
EGFP template DNA (5’-Pm1I, 3’-BglII) into the 5’-AscI, 3’-PacI sites of pX330 CARM1-
I3F/CARM1-I4F (Cas9-WT KBL#409/408) construct. PCR-analysis was used to confirm 
WT, knock-in (KI), and recombined (KO) CARM1. 
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RA treatments and RNA isolation. 
J1 mESC lines were treated with vehicle (0.1% EtOH) or 1 μM RA for 24-72 hrs, 
with RA replaced every 48 hrs. Total RNA was isolated using TRIzol (Invitrogen) 
according to the manufacturer’s protocol. RNA (2 μg) was reverse-transcribed to cDNA 
using qScript (Quanta Biosciences). 2 µL of 1:10 diluted cDNA was used for all semi-
quantitative (sq)-PCR reactions. 
Semi-quantitative and quantitative RT-PCR analyses. 
cDNA RT-PCR amplification for sq-PCR was performed using Taq DNA 
polymerase (Invitrogen) (20 µL reaction volume). Using a Bio-Rad iCycler, each cycle 
included: denaturation: 95°C (30s), annealing: 58–65°C (30s), and extension: 72°C 
(45s). PCR products were separated by electrophoresis on an ethidium bromide stained 
1-2% agarose gel. ImageJ software (National Institutes of Health) was used to 
quantitate band densities and we normalized cDNA product to the internal reference 
gene 36B4. qRT-PCR reactions (15 µL) were carried out using SYBR Green 
quantitative PCR master mix. Specific primer sequences for each gene are shown 
(Supplemental Table 2). 
Protein extraction and Western Blot analysis. 
We isolated protein53 and performed western blotting (25-30 µg protein) as 
previously described54 using the following primary antibodies: anti-CARM1 (Millipore, 
cat# 09-818, lot# 2036700, 1:1000); anti-Actin (Cell Signaling, cat# MAB1501, lot# 
2275539 & 2665057, 1:80,000); anti-me-PABP1 (gift from Dr. Wei Xu, 1:1000); anti-
Nanog (Cell Signaling, cat# 4903P, lot# 1, 1:1000); anti-Oct3/4 (Santa Cruz, cat# 8629, 
lot# K1308, 1:250), and secondary antibodies: anti-goat (Santa Cruz, cat# sc2020, lot 
#H1715, 1:10,000); anti-rabbit (Jackson ImmunoResearch, cat# 715-035-152, lot# 
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1117118 & 22884, 1:10,000); anti-mouse (Jackson ImmunoResearch, cat# 715-035-
150, lot# 116722 & 123115, 1:10,000). Membranes were developed using the Western 
Pierce ECL Plus Substrate kit (ThermoFisher). 
Chromatin Immunoprecipitation (ChIP) assays. 
We cultured J1 WT and CARM1 KO #23 cells with or without 1 µM RA for 24-72 
hrs. Cells were plated at ~0.3 x 106 (72 hr), ~ 0.9 x 106 (48 hr), and ~2.5 x 106 (24hr) on 
consecutive days to collect all time points for ChIP processing on the same day. Cells 
were crosslinked using a one-step (H3K27ac, H3K27me3) or two-step (CARM1, Suz12) 
ChIP protocol as described previously in the lab54, 55. Cells were sonicated and the 
precleared lysates (25 µg DNA) were immunoprecipitated using 0.5–2.0 µg of 
antibodies specific for CARM1 (Epicypher, Research Triangle Park, NC, cat# 13-0006, 
lot# 13281001), H3K27ac (Abcam, cat# 4729, lot# GR28147), H3K27me3 (Abcam, cat# 
6002, lot# 2736613), H3R17me2a (Abcam, cat# 8284, lot# GR295369-1), Suz12 (Cell 
Signaling, cat# D39F6, lot# 3), or IgG (Santa Cruz, cat# sc2027, lot# L2414) (negative 
control). We purified DNA using the Qiagen PCR purification kit and used 3 µL for qPCR 
analysis. We used DNA input samples diluted 1:10 (2.5 µg) to normalize 
immunoprecipitated DNA. ChIP analyses were performed at least three times for each 
IP (n ≥ 3). 
RNA-seq/Genome-wide Transcriptomics. 
J1 WT, shCtl, and CARM1 KD cells were treated with or without RA as described 
above for 48 hrs. We extracted RNA using the Qiagen RNeasy Plus Kit. Samples were 
submitted to the Weill Cornell Genomics Resources Core Facility for Next-Generation 
Sequencing (RNA-Seq) as previously described56. The total number reads and the 
number of aligned reads are listed in Supplemental Table 3. Dr. Tuo Zhang (Weill 
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Cornell Genomics Core Facility) aligned the reads to the mouse mm9 reference 
genome using Tophat257 and gene expression values were measured in RPKM using 
cufflinks58. The RNA-seq data were deposited in GEO (NCBI) repository under 
accession number GSE115818. 
We filtered our RNA-seq data for genes that were ≥ 2-fold increased with RA 
treatment in the shCtl cells compared to the vehicle treated shCtl cells. We set a cutoff 
of 0.5 RPKM in the shCtl RA treated cells, which resulted in 2,840 genes. We also 
considered genes whose values were ≥ 1.5-fold increased with RA in the J1 parental 
cells and ≥ 0.5 RPKM. RA-induction of most transcripts was higher in the shCtl cells 
compared to the J1 parental cells and chose 1.5 rather than 2-fold RA-induction in the 
parental cells as one of our parameters. This resulted in 2,356 genes induced by RA in 
the J1 parental and shCtl control cell lines. We next considered genes whose transcript 
levels were ≥ 2-fold higher in the shCtl RA treated cells and ≥ 1.5-fold higher in the J1 
parental RA-treated cells compared to the CARM1 KD RA-treated cells. This resulted in 
101 genes whose RA-induction requires CARM1.  
Statistical analyses of data. 
We used Microsoft Excel to calculate the mean values and standard errors of 
mean (SE). Transcript levels are normalized to 36B4 or HPRT and protein expression is 
normalized to Actin. We used one-way ANOVA followed by the Tukey post hoc test to 
determine statistical significance among groups (GraphPad Prism 7). Values for ChIP-
qPCR are normalized to their respective input samples and represented as relative 
occupancy to the J1 vehicle control sample, set to 1. We used student’s t-test to 
compare the two cell lines at each time point for ChIP-qPCR analysis. 
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FIGURE LEGENDS. 
Figure 1: Generation of CARM1 KD and KO mESCs. 
A) J1 WT mESCs were either treated with vehicle (Veh. Ctl.) or 1 µM RA for 24-
72 hrs. CARM1 mRNA levels were measured by semi-quantitative PCR (semi-qPCR). 
Images are from one experiment of three biological repeats and HPRT is used as the 
loading control to normalize CARM1 mRNA values. B) J1 WT mESCs were untreated 
(No Tx) or treated as in A) and CARM1 protein levels were measured using western blot 
(WB) analysis (n=3). Actin is used as the loading control to normalize CARM1 protein 
values. C) Stable CARM1 knockdown (KD, #9117) and knockout (KO, #23) mESCs 
were generated as mentioned in the methods section. We used WB analysis to confirm 
the CARM1 KD and KO cell lines. The images are from one experiment of three 
biological repeats starting from the generation of lentiviral particles in HEK293T cells for 
the CARM1 KD cell lines. D) me-Pabp1 protein levels were measured by WB analysis in 
the CARM1 KD (#9117) and CARM1 KO (#23) cell lines to compare CARM1 depletion 
efficiency (n=3). E) Cell lines were plated in 12-well plates and counted 24hrs after initial 
plating for three consecutive days (n=3). ImageJ was used to measure mRNA band 
densities and Image Lab was used to measure protein band densities. Fold change is 
represented as the difference between each sample relative to WT Veh. Ctl, which is 
set to 1. Statistical significances were calculated using one-way ANOVA followed by the 
Tukey post hoc test (****p<0.0001). 
 
Figure 2: Effects of CARM1 loss on pluripotency transcripts. 
A) J1 WT, shCtl, CARM1 KD (# 9117), and CARM1 KO (#23) cells were plated in 
6-well plates and treated with 1 μM RA for 48 hrs following 24 hrs after initial plating for 
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each biological repeat (n=3). mRNA levels were measured by qRT-PCR and normalized 
to 36B4 control mRNA levels using the delta CT method. To determine relative mRNA 
levels, we compared values to the highest signal, which was set to 1. B) J1 WT and 
CARM1 KO (#23) cells were plated in 6mm plates and harvested for protein isolation. 
Nanog and Oct4 protein levels were measured using western blot (WB) analysis. 
Images are from one experiment of three biological repeats. Actin is used as the loading 
control and Image Lab was used to measure protein band densities to generate the bar 
graphs. Statistical differences were calculated using one-way ANOVA followed by the 
Tukey post hoc test (*p<0.05, **p<0.01, ***p<0.001).  
 
Figure 3: CARM1 is required for induction of a subset of RA-regulated genes. 
 A) J1 WT, shCtl, CARM1 KD (# 9117), and CARM1 KO (#23) cells were plated in 
6-well plates and treated with RA for 48 hrs following 24 hrs after initial plating for each 
biological repeat (n=3). mRNA levels were measured by semi-quantitative PCR (semi-
qPCR) and 36B4 is used as the loading control. B) ImageJ was used to measure the 
semi-qPCR band densities shown in A) to generate the bar graphs. Band densities for 
each gene were normalized to 36B4. To determine relative mRNA expression, the most 
intense band was set to 1 (n=3, except Cyp26b1 is n=1). Statistical differences were 
calculated using one-way ANOVA followed by the Tukey post hoc test (**p<0.01, 
***p<0.001, ****p<0.0001). These data were then replicated by using genome-wide RNA 
transcriptomic profiling (Supplemental Table 1). 
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Figure 4: CARM1 is required for RA-induced extraembryonic endoderm 
differentiation. 
A) J1 WT and CARM1 KO (#23) cells were plated in 6-well plates and treated 
with RA for 48 and 72 hrs following 24 hrs after initial plating for each biological repeat 
(n≥3). Images are from one experiment. mRNA levels were measured by semi-
quantitative PCR (semi-qPCR) and 36B4 is used as the loading control. B) ImageJ was 
used to measure the semi-qPCR band densities for each repeat to generate the bar 
graphs. Band densities for each gene were normalized to 36B4. To determine relative 
mRNA levels, we compared values to the most intense band, which was set to 1. For 
Sox17, a band was only detected in the J1 parental cells at 72 hrs after RA treatment, 
as is seen in the gel image; therefore, significant changes could not be calculated. 
Statistical differences were calculated using one-way ANOVA followed by the Tukey 
post hoc test (****p<0.0001). 
 
Figure 5: CARM1 is present at RA responsive regions of RA-inducible target 
genes. 
A) A representative scheme showing the regions used for chromatin 
immunoprecipitation (ChIP) relative to each transcriptional start site (TSS) for each 
gene. The bent arrows indicate the TSS. PRefSeq is a putative TSS previously identified 
and characterized in our lab. B) We plated J1 WT cells in 150mm plates and 24 hrs 
after initial plating for each biological repeat we added 1 µM RA for 24, 48, and 72 hrs. 
The vehicle control (Veh. Ctl.) plates were plated at the same time as the 48hr RA 
plates. 25µg of ChIP lysate was used with 5µL of CARM1 antibody for the 
immunoprecipitation (IP). qPCR was used to measure CARM1 occupancy at each gene 
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region shown. IPs for IgG and CARM1 KO Veh. Ctl. were used as negative controls. 
Graphs represent the average of three biological repeats. To determine relative 
occupancy, the J1 WT Veh. Ctl. samples were set to 1 for each IP. The percent input 
values set to 1 for each J1 WT Veh. Ctl. are 0.03 (Hoxa1), 004 (NR2F1), and 0.03 
(CRABP2). Statistical differences were calculated using one-way ANOVA followed by 
the Tukey post hoc test (*p<0.005, (**p<0.01, ***p<0.001).  
 
Figure 6: CARM1 depletion affects the chromatin signatures on CRABP2 and 
NR2F1. 
A) J1 WT and CARM1 KO (# 23) cells were plated and treated as in Fig. 5B. 
25µg of ChIP lysate were used with 5µL of Suz12 antibody for the immuniprecipitation 
(IP). qPCR was used to measure Suz12 occupancy at each gene region shown. The IP 
for IgG is used as a negative control and the J1 WT Veh. Ctl. samples were set to 1 for 
each IP to determine relative occupancy. The percent input values set to 1 for each J1 
WT Veh. Ctl. are 0.70 (Hoxa1), 5.97 (NR2F1), and 0.37 (CRABP2). B) Cells were 
plated as in A) and 2µL of the H3K27me3 antibody were used. The percent input values 
set to 1 for each J1 WT Veh. Ctl. are 1.44 (Hoxa1), 0.28 (NR2F1), and 0.14 (CRABP2). 
C) Cells were plated as in A) and 0.5µL of the H3K27ac antibody were used. The 
percent input values set to 1 for each J1 WT Veh. Ctl. are 0.48 (Hoxa1), 0.31 (NR2F1), 
and 0.43 (CRABP2). All graphs represent the average of at least three biological 
repeats. We used Student’s t-test to determine statistical differences at each time point 
after RA treatment between the two cell lines for NR2F1 PRefSeq and CRABP2 RARE1 
(*p<0.05, **p<0.01, ****p<0.0001). For the Hoxa1 RARE, statistical differences were 
calculated using one-way ANOVA followed by the Tukey post hoc test to compare the 
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J1 and KO Veh. Ctl. to J1 and KO 24-72 hrs RA samples (****p<0.0001). 
 
Figure 7: Representative model depicting the differences between RA-inducible 
genes that require CARM1 (ii, iii) and those that do not (i). 
In the absence of RA, CARM1 is present and both these gene sets are 
associated with co-repressors and repressive histone marks, such as H3K27me3. For 
those genes not affected upon CARM1 depletion (e.g. Hoxa1), Suz12 (representative of 
the PRC2 complex) and H3K27me3 are rapidly removed after RA addition and are no 
longer present at the RARE. Co-activators are then recruited to initiate transcription, 
along with an increase in activating histone marks (e.g. H3K27ac) independent of 
CARM1’s occupancy (i). Thus, CARM1 is bound at the Hoxa1 RARE +/- RA but does 
not influence RA-associated transcriptional activation, so CARM1 is not shown. For 
genes requiring CARM1 for their RA-induced transcriptional activation (i.e. NR2F1, 
CRABP2), Suz12 (representative of PRC2) and the H3K27me3 mark gradually 
decrease (NR2F1) or do not change (CRABP2) and are not completely removed with 
the addition of RA in WT cells. For NR2F1, lack of CARM1 prevents the decrease in 
Suz12 (representative of PRC2) and the H3K27me3 mark upon RA addition (ii). Lack of 
CARM1 also increases Suz12 level (representative of PRC2) at the RARE1 of 
CRABP2, but does not affect the H3K27me3 level. There is also an increase in the 
H3K27ac level at CRABP2 after RA addition in WT cells, and the absence of CARM1 
blocks this increase in H3K27ac (iii). There are no changes in the H3K27ac level at 
NR2F1 upon RA addition. CARM1 facilitates this differential modulation of epigenetic 
regulators upon RA treatment to allow RA-induced transcriptional activation of CRABP2 
and NR2F1. 
